A Phase 2 Randomized, Double-blind, Placebo-controlled, 3-arm, Parallel-design Study of the Efficacy and Safety of VX-150 for Acute Pain Following Bunionectomy

Trial Profile

A Phase 2 Randomized, Double-blind, Placebo-controlled, 3-arm, Parallel-design Study of the Efficacy and Safety of VX-150 for Acute Pain Following Bunionectomy

Completed
Phase of Trial: Phase II

Latest Information Update: 14 Feb 2018

At a glance

  • Drugs VX 150 (Primary) ; Hydrocodone/paracetamol
  • Indications Pain
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Vertex Pharmaceuticals
  • Most Recent Events

    • 14 Feb 2018 Primary endpoint (Time-weighted sum of the pain intensity difference between VX-150 versus placebo as recorded on a Numeric Pain Rating Scale (NPRS)-VX-150 compared to placebo) has been met, according to results presented in a Vertex Pharmaceuticals media release.
    • 14 Feb 2018 Results presented in a Vertex Pharmaceuticals media release.
    • 31 Jan 2018 According to a Vertex Pharmaceuticals media release, the company anticipates data from this trial in the first quarter of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top